Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Deniz Can GÜVEN"'
Autor:
Feride Yılmaz, Serkan Yaşar, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Deniz Can Güven, Arif Akyıldız, Elvin Chalabiyev, Burak Yasin Aktaş, Zafer Arık, Mustafa Erman
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC. In the second line, weekly or three-weekly irinotecan regimen
Externí odkaz:
https://doaj.org/article/d05ee6cbcd604c23bdd7f7e674ff535f
Autor:
Burak Yasin Aktaş, Emine Büşra Ata, Engin Çeşmeci, İbrahim Yahya Çakır, Muharrem Coşkunpınar, Yağmur Tahillioğlu, Gürkan Güner, Deniz Can Güven, Zafer Arık, Neyran Kertmen, Ömer Dizdar, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9689-9700 (2023)
Anemia remains an essential concern affecting the quality of life and the survival of cancer patients. Although there are different approaches to treating anemia in cancer patients, the number of studies reporting the efficacy of iron replacement in
Externí odkaz:
https://doaj.org/article/f55f571aa8f04f59a35f393210fd57cc
Autor:
Çağlar Ünal, Çetin Ordu, Tolga Özmen, Ahmet Serkan İlgun, Filiz Çelebi, Bülent Baysal, Enver Özkurt, Tomris Duymaz, Zeynep Erdoğan İyigün, Sevgi Kurt, Mehmet Alper Öztürk, Kezban Nur Pilancı, Gül Alço, Kanay Yararbaş, Tuba Kayan Tapan, Deniz Can Güven, Gürsel Soybir, Vahit Özmen
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 9217-9229 (2023)
Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive than those of E2, FSH, and i
Externí odkaz:
https://doaj.org/article/22ea879de88644029998ba26a0023112
Autor:
Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, Miraç Özen, Merve Keskinkılıç, Sercan Ön, Abdussamet Çelebi, Bengü Dursun, Ömer Acar, Seda Kahraman, Musa Barış Aykan, Ömür Kaman, Akif Doğan, Atike Pınar Erdoğan, Özde Melisa Celayir, Damla Günenç, Deniz Can Güven, İbrahim Vedat Bayoğlu, Tuğba Yavuzşen, İlhan Hacıbekiroğlu, Mevlüde İnanç, Saadettin Kılıçkap, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Breast, Vol 66, Iss , Pp 85-88 (2022)
Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), h
Externí odkaz:
https://doaj.org/article/18da86563ce64050a659105850fa47be
Autor:
Hasan Çağrı YILDIRIM, Meral ÜNER, Tuğba YILDIRAN ÖZMEN, Elvin CHALABIYEV, Deniz Can GÜVEN, Fatih KUŞ, Arif AKYILDIZ, Feride YILMAZ, Serkan YAŞAR, Yasemin EVLENDİ, Ömer DİZDAR, Şuayib YALÇIN, Ayşegül ÜNER, Sercan AKSOY
Publikováno v:
Journal of Oncological Sciences. 9:33-37
Autor:
Mustafa Gürbüz, Yasin Kutlu, Erman Akkuş, Elif Berna Köksoy, Naziyet Köse, Bala Başak Öven, Başak Oyan Uluç, Atike Gökçen Demiray, Dilek Erdem, Bilgin Demir, Nazım Serdar Turhal, Necdet Üskent, Sinem Akbaş, Fatih Selçukbiricik, Ali İnal, Ahmet Bilici, Ömer Fatih Ölmez, Devrim Çabuk, Çağlar Ünal, Mutlu Hızal, Mehmet Ali Nahit Şendur, Mustafa Korkmaz, Nuri Karadurmuş, İsmail Ertürk, Sema Sezgin Göksu, Ali Murat Tatlı, Deniz Can Güven, Saadettin Kılıçkap, Nail Paksoy, Adnan Aydıner, Havva Yeşil Çınkır, Özlem Özkul, Akın Öztürk, Sevinç Ballı, Yasemin Kemal, Atike Pınar Erdoğan, Özlem Er, Perran Fulden Yumuk, Ahmet Demirkazık
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:3547-3555
Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to deter
Autor:
Elsa Vitale, Alessandro Rizzo, Lorenza Maistrello, Deniz Can Guven, Raffaella Massafra, Veronica Mollica, Fernando Sabino Marques Monteiro, Matteo Santoni, Francesco Massari
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Immune checkpoint inhibitors have revolutionized cancer treatment, but they are associated with a range of immune-related adverse events (irAEs), and emerging evidence suggests significant sex differences in the incidence, type, and severity
Externí odkaz:
https://doaj.org/article/4974ac2fb29b4bf78496dcf866495416
Autor:
Hasan Çağrı YILDIRIM, Deniz Can GÜVEN, Elvin CHALABIYEV, Hakan TABAN, Feride YILMAZ, Serkan YAŞAR, Fatih KUŞ, Arif AKYILDIZ, Süleyman Çağın GÜRBÜZ, Hüseyin SAYIN, Gözde KAVGACI, Şuayib YALÇIN, Ömer DİZDAR
Publikováno v:
Journal of Oncological Sciences. 8:143-147
Autor:
Görkem Yazıcı Şener, Osman Sütcüoğlu, Betül Öğüt, Deniz Can Güven, Altan Kavuncuoğlu, Nuriye Özdemir, Ahmet Özet, Sercan Aksoy, Yeşim Gaye Güler Tezel, Nalan Akyürek, Ozan Yazıcı
Publikováno v:
Strahlentherapie und Onkologie.
Autor:
Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, Nuri Karadurmuş, Ahmet Sezer, Mehmet Ali Nahit Şendur, Semra Paydaş, Mehmet Artaç, Perran Fulden Yumuk, Pinar Gürsoy, Mükremin Uysal, Hasan Şenol Coşkun, Ali Murat Tatli, Fatih Selçukbiricik, Umut Dişel, Elif Berna Köksoy, Deniz Can Güven, Muzaffer Uğrakli, Erman Akkuş, Şebnem Yücel, Cihan Erol, Serdar Karakaya, Teoman Şakalar, Nijat Khanmammadov, Nail Paksoy, Ahmet Demirkazik
Publikováno v:
Medicine. 101(50)
Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterat